New Irish research published in BMJ Open has found that young people aged 16-17 years old believe standardised packs to be less attractive and their cigarettes to be more harmful than packs with EU Tobacco Products Directive (TPD) labels, which includes picture and text warning covering 65 per cent of the packages.
New research from Austria has found no evidence that lithium-based pharmaceuticals either directly or via accumulation in drinking water diminish the risk of death by suicide.
In the largest prospective study to date of image-guided technology for identifying suspicious regions of the prostate to biopsy, researchers compared the ability of this technology to detect high-risk prostate cancer with that of the current standard of unguided prostate biopsy.
In the years to come, personalised medicine will be the goal, Gary Culliton reports in his latest Clinical Update. It is a promising area: now much effort is devoted to studying combinations of different therapies.
Colorectal cancer is a treatable disease and there are a number of effective options available. Progress has been made in diagnosing the disease earlier. Data on which treatment works best in the early stages of the cancer is now being sought.
Bowel cancer survival has more than doubled in the last 40 years. But much work remains. Key partners have come together to develop new ways to tailor treatment to the patients who will benefit the most, and to make a difference to their chances of beating this common disease.
An analysis of a major integrated primary healthcare programme in Mexico has shown that significant reductions in mortality rates may be explained by both changes in incidence rates and changes in case fatality rates associated with early detection and treatment.
Pilot studies in UK and Australian primary schools has suggested that the introduction of so-called ‘sit-to-stand desks’ appears to be an effective way of reducing classroom sitting and tackling children’s sedentary behaviour.
Clearly, not every prostate cancer patient will benefit from novel endocrine treatments, Gary Culliton reports in his latest Clinical Update. Thus, personalised medicine is key. The challenge now is to identify which patients will benefit from the drugs and which will not.
Cruinn Diagnostics is proud to launch the new Xprecia Stride analyser in partnership with Siemens Healthcare Diagnostics.
So small, it can fit in your pocket. So accurate, it could go in a lab. The new Xprecia Stride Coagulation Analyzer brings accuracy to the point of care.